Concord Healthcare Group Co., Ltd. – Major Milestone in Proton Therapy Business
Key Highlights
- Guangzhou Concord Cancer Center’s Proton Therapy Center has been officially operational for 18 months as of May 2026.
- Over 880 patients treated to date, with the daily patient volume exceeding 100.
- Patients served are from 31 provincial-level regions across China and over 20 countries worldwide.
- Patient age range is broad, from 13 months old children to 91 years old seniors.
- The Center treats a wide variety of malignant tumors, including childhood tumors, CNS tumors, head and neck cancers (e.g. nasopharyngeal carcinoma), thoracic cancers (e.g. lung, esophageal), breast, abdominal (e.g. liver), urinary (e.g. prostate), and soft tissue sarcomas.
- Management plans to further optimize service processes and improve diagnosis and treatment efficiency to deliver high-quality, precision proton therapy to more oncology patients.
Details for Investors
The Board of Concord Healthcare Group Co., Ltd. has announced a significant operational achievement: the company’s flagship Guangzhou Hospital Proton Center, a subsidiary, has treated over 880 patients since becoming operational 18 months ago. This marks a new milestone in the precision radiotherapy sector for tumors in South China. Notably, the daily patient volume has surpassed 100, demonstrating both strong demand and operational efficiency.
The Center’s reach is extensive, attracting patients not only from all 31 provincial-level administrative regions in mainland China but also from more than 20 countries worldwide. The wide age coverage (from infants as young as 13 months to elderly patients up to 91 years old) highlights the adaptability and advanced capabilities of the center’s treatment protocols.
The therapy scope includes a full range of malignant tumors, with a particular emphasis on childhood tumors, central nervous system tumors, head and neck tumors (such as nasopharyngeal carcinoma), thoracic tumors (including lung and esophageal cancer), breast tumors, abdominal tumors (such as liver cancer), urinary system tumors (such as prostate cancer), and soft tissue sarcomas. This indicates the center’s comprehensive expertise and advanced equipment.
The company’s management has committed to continuous improvement by optimizing service processes and enhancing diagnostic and treatment efficiency. This strategy is aimed at expanding the center’s capacity, improving patient outcomes, and maintaining the high quality of its precision proton therapy services.
Potential Impact on Shareholders and Share Price
- Rapid growth in patient numbers and the high daily volume signal robust demand and may lead to increased revenue and improved financial performance.
- The center’s international appeal and comprehensive tumor treatment portfolio position Concord Healthcare as a major player in precision oncology services in Asia.
- Operational achievements and continued investment in process optimization may positively affect the company’s reputation, competitiveness, and long-term growth prospects.
- These developments are potentially price-sensitive and could influence share value as they reflect the company’s ability to execute its growth strategy and expand its market reach.
Board and Governance
The Board comprises Dr. YANG Jianyu and Mr. JIANG Wei as executive Directors; Mr. WANG Lei, Mr. SONG Qingbao, and Mr. SHI Botao as non-executive Directors; Ms. LI Xuemei, Mr. SUN Yansheng, and Mr. NG Kwok Yin as independent non-executive Directors; and Ms. JIANG Li as employee Director.
Shareholder Advisory
Shareholders and potential investors are advised to exercise caution when dealing in the shares of the company, as developments in the proton therapy business are material and may affect share value.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should exercise independent judgment and consult professional advisors before making investment decisions.
協和醫療集團有限公司——質子治療業務重大進展（廣東話版本）
重點摘要
- 廣州協和腫瘤中心質子治療中心截至2026年5月已正式運營18個月。
- 累計服務超過880名患者，單日就診人數突破100人。
- 患者來自中國31個省級行政區及全球超過20個國家。
- 患者年齡由13個月大幼童至91歲長者皆有覆蓋。
- 治療範疇廣泛，包括兒童腫瘤、中樞神經系統腫瘤、頭頸部腫瘤（如鼻咽癌）、胸腔腫瘤（如肺癌、食道癌）、乳腺腫瘤、腹部腫瘤（如肝癌）、泌尿系統腫瘤（如前列腺癌）、及軟組織肉瘤等。
- 管理層正計劃持續優化服務流程，提升診療效率，致力為更多腫瘤患者提供高質素精準質子治療服務。
投資者需知詳情
董事會宣布，協和醫療集團下屬的廣州協和腫瘤中心質子治療中心自正式運營18個月以來，累計服務超過880名患者，單日就診量超過100人，標誌著華南地區腫瘤精準放療能力的新里程碑。
中心服務範圍廣泛，患者來自全國31個省級行政區及超過20個國家，年齡由13個月大幼童至91歲長者，體現了中心治療技術的先進與多樣化。
中心治療腫瘤類型涵蓋兒童腫瘤、中樞神經系統腫瘤、頭頸部腫瘤（如鼻咽癌）、胸腔腫瘤（包括肺癌、食道癌）、乳腺腫瘤、腹部腫瘤（如肝癌）、泌尿系統腫瘤（如前列腺癌）、及軟組織肉瘤等，顯示中心臨床能力全面。
公司管理層表示，將持續優化服務流程，提升診療效率，進一步擴大服務能力，為更多患者帶來高質量的質子放療。
對股東及股價的潛在影響
- 患者數量快速增長及高日均服務量，預示著收入提升及財務表現改善。
- 中心擁有國際吸引力及全面腫瘤治療能力，鞏固協和醫療於亞洲精準腫瘤治療領域的重要地位。
- 運營成就與持續優化，有助提升公司聲譽、競爭力及長遠增長前景。
- 上述發展屬於潛在敏感信息，或對公司股價產生影響，反映公司執行增長策略及擴展市場的能力。
董事會及管治
現任董事會成員包括：執行董事楊建宇博士、蔣偉先生；非執行董事王磊先生、宋慶保先生、石博濤先生；獨立非執行董事李雪梅女士、孫延生先生、吳國賢先生；及員工董事蔣莉女士。
股東提示
股東及潛在投資者應謹慎處理公司股份交易，因質子治療業務的發展屬重大事項，或影響公司股價。
免責聲明：本文僅供參考，並不構成任何投資建議。投資者應獨立判斷，並諮詢專業顧問後作出投資決定。
